New yellow fever vaccine shows promise in early safety trial
NCT ID NCT05172544
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This Phase 1 trial tested an inactivated yellow fever vaccine called HydroVax-002 YFV in 26 healthy adults. Participants received two doses of either the vaccine or a placebo. The main goal was to check safety and side effects, while also measuring immune response. The trial is complete, but results are not yet public.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- HydroVax-002 YFV (inactivated yellow fever virus vaccine)
- What this could lead to
- If successful, this could lead to a safer yellow fever vaccine, especially for people who cannot receive the current live vaccine.
- What could go wrong
- This is an early Phase 1 trial with only 26 people, so it is too soon to know if the vaccine will work in larger populations or be widely approved.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for YELLOW FEVER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Duke University Health System
Durham, North Carolina, 27705, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New yellow fever vaccine shows promise in Mid-Stage trial
- New vaccines for yellow fever and rabies enter first human tests
- New yellow fever vaccine shows promise in early human trial
- 10,000 people tested: Cambodia's massive disease hunt begins
- Scientists use yellow fever vaccine to map immune System's battle plan
- New yellow fever vaccine shows promise in japanese adults